The patent application discloses a therapeutic method for treating bronchiectasis patients co-infected with nontuberculous mycobacteria (NTM) through nitric oxide administration for a minimum of 100 days. The inventors claim the extended treatment regimen improves functional capacity and quality of life outcomes. The application is classified under CPC codes A61M 16/12, A61M 16/026, and A61M 2202/0275, indicating nitric oxide delivery apparatus for respiratory therapy.

This is a patent application publication only—no compliance obligations or regulatory deadlines apply. Healthcare providers and medical device manufacturers should note this intellectual property filing for competitive intelligence and potential licensing considerations. If the patent is granted, it may affect market entry for competing nitric oxide-based respiratory therapies targeting bronchiectasis/NTM patients.